WO2022171147A1 - 嘧啶并芳香环类化合物 - Google Patents
嘧啶并芳香环类化合物 Download PDFInfo
- Publication number
- WO2022171147A1 WO2022171147A1 PCT/CN2022/075732 CN2022075732W WO2022171147A1 WO 2022171147 A1 WO2022171147 A1 WO 2022171147A1 CN 2022075732 W CN2022075732 W CN 2022075732W WO 2022171147 A1 WO2022171147 A1 WO 2022171147A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- added
- reaction
- synthesis
- pharmaceutically acceptable
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims abstract description 695
- 150000003839 salts Chemical class 0.000 claims abstract description 62
- -1 hexahydro - 1H-pyrrolizinyl Chemical group 0.000 claims description 75
- 229910052731 fluorine Inorganic materials 0.000 claims description 61
- 229910052801 chlorine Inorganic materials 0.000 claims description 60
- 229910052739 hydrogen Inorganic materials 0.000 claims description 44
- 125000000217 alkyl group Chemical group 0.000 claims description 39
- 125000003545 alkoxy group Chemical group 0.000 claims description 32
- 102200006539 rs121913529 Human genes 0.000 claims description 32
- 206010028980 Neoplasm Diseases 0.000 claims description 28
- 229910052794 bromium Inorganic materials 0.000 claims description 28
- 125000003342 alkenyl group Chemical group 0.000 claims description 26
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 25
- 229910052736 halogen Inorganic materials 0.000 claims description 22
- 150000002367 halogens Chemical group 0.000 claims description 22
- 229910052740 iodine Inorganic materials 0.000 claims description 22
- 125000003118 aryl group Chemical group 0.000 claims description 17
- 229910052799 carbon Inorganic materials 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 15
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 14
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 14
- 238000002360 preparation method Methods 0.000 claims description 12
- 125000000304 alkynyl group Chemical group 0.000 claims description 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 10
- 238000006467 substitution reaction Methods 0.000 claims description 10
- 230000035772 mutation Effects 0.000 claims description 9
- 229910052760 oxygen Inorganic materials 0.000 claims description 9
- 125000004366 heterocycloalkenyl group Chemical group 0.000 claims description 8
- 125000001624 naphthyl group Chemical group 0.000 claims description 8
- 125000003554 tetrahydropyrrolyl group Chemical group 0.000 claims description 8
- 206010009944 Colon cancer Diseases 0.000 claims description 7
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 7
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 6
- 125000004076 pyridyl group Chemical group 0.000 claims description 6
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 150000001345 alkine derivatives Chemical class 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 3
- 125000005493 quinolyl group Chemical group 0.000 claims description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 473
- 238000006243 chemical reaction Methods 0.000 description 275
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Substances CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 205
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 179
- 238000003786 synthesis reaction Methods 0.000 description 163
- 230000015572 biosynthetic process Effects 0.000 description 162
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 148
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 148
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 140
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 122
- 239000000243 solution Substances 0.000 description 121
- 239000012043 crude product Substances 0.000 description 116
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 108
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 102
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 83
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 81
- 229910052757 nitrogen Inorganic materials 0.000 description 79
- 239000003208 petroleum Substances 0.000 description 74
- 239000012074 organic phase Substances 0.000 description 69
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 54
- 210000004027 cell Anatomy 0.000 description 53
- 239000000460 chlorine Substances 0.000 description 52
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 51
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 48
- 235000002639 sodium chloride Nutrition 0.000 description 46
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 42
- 238000010828 elution Methods 0.000 description 42
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 41
- 239000012071 phase Substances 0.000 description 41
- 239000000741 silica gel Substances 0.000 description 41
- 229910002027 silica gel Inorganic materials 0.000 description 41
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 36
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 30
- 239000000203 mixture Substances 0.000 description 30
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 26
- 239000000706 filtrate Substances 0.000 description 26
- 238000012360 testing method Methods 0.000 description 25
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 24
- 239000007787 solid Substances 0.000 description 24
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 24
- 238000000034 method Methods 0.000 description 23
- 238000000926 separation method Methods 0.000 description 23
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 23
- 239000012065 filter cake Substances 0.000 description 22
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 22
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 22
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 21
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 20
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 20
- 229910000024 caesium carbonate Inorganic materials 0.000 description 20
- 238000004440 column chromatography Methods 0.000 description 20
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 20
- 102100030708 GTPase KRas Human genes 0.000 description 19
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 description 19
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 18
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 16
- 239000008346 aqueous phase Substances 0.000 description 16
- 230000005764 inhibitory process Effects 0.000 description 16
- 108090000623 proteins and genes Proteins 0.000 description 16
- 102000004169 proteins and genes Human genes 0.000 description 16
- 239000002904 solvent Substances 0.000 description 16
- 150000004675 formic acid derivatives Chemical class 0.000 description 15
- 238000003756 stirring Methods 0.000 description 15
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 14
- 239000000872 buffer Substances 0.000 description 14
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 14
- 125000004432 carbon atom Chemical group C* 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 12
- 230000002401 inhibitory effect Effects 0.000 description 12
- 229910000160 potassium phosphate Inorganic materials 0.000 description 12
- 235000011009 potassium phosphates Nutrition 0.000 description 12
- 238000000746 purification Methods 0.000 description 12
- 229910000029 sodium carbonate Inorganic materials 0.000 description 12
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 11
- 239000002585 base Substances 0.000 description 11
- XJHCXCQVJFPJIK-UHFFFAOYSA-M caesium fluoride Chemical compound [F-].[Cs+] XJHCXCQVJFPJIK-UHFFFAOYSA-M 0.000 description 11
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 11
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 11
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 10
- 239000002253 acid Substances 0.000 description 10
- 229910002092 carbon dioxide Inorganic materials 0.000 description 10
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 10
- 229910000027 potassium carbonate Inorganic materials 0.000 description 10
- 229940086542 triethylamine Drugs 0.000 description 10
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 9
- 239000012141 concentrate Substances 0.000 description 9
- 238000000502 dialysis Methods 0.000 description 9
- 235000019253 formic acid Nutrition 0.000 description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Chemical compound IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 8
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000003480 eluent Substances 0.000 description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 8
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 8
- 125000001424 substituent group Chemical group 0.000 description 8
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 8
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 7
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 239000001569 carbon dioxide Substances 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 239000002994 raw material Substances 0.000 description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 6
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 6
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 235000011114 ammonium hydroxide Nutrition 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 125000005842 heteroatom Chemical group 0.000 description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 6
- 238000001990 intravenous administration Methods 0.000 description 6
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 6
- 238000003032 molecular docking Methods 0.000 description 6
- MFIGJRRHGZYPDD-UHFFFAOYSA-N n,n'-di(propan-2-yl)ethane-1,2-diamine Chemical compound CC(C)NCCNC(C)C MFIGJRRHGZYPDD-UHFFFAOYSA-N 0.000 description 6
- IVDFJHOHABJVEH-UHFFFAOYSA-N pinacol Chemical compound CC(C)(O)C(C)(C)O IVDFJHOHABJVEH-UHFFFAOYSA-N 0.000 description 6
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 6
- 238000002953 preparative HPLC Methods 0.000 description 6
- 238000004237 preparative chromatography Methods 0.000 description 6
- 238000010898 silica gel chromatography Methods 0.000 description 6
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 6
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 6
- 239000012224 working solution Substances 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 125000004429 atom Chemical group 0.000 description 5
- 239000004202 carbamide Substances 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 150000002430 hydrocarbons Chemical group 0.000 description 5
- 125000005647 linker group Chemical group 0.000 description 5
- 229910052763 palladium Inorganic materials 0.000 description 5
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 125000006413 ring segment Chemical group 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000013592 cell lysate Substances 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 238000012054 celltiter-glo Methods 0.000 description 4
- 208000029742 colonic neoplasm Diseases 0.000 description 4
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- 238000007405 data analysis Methods 0.000 description 4
- LZWLLMFYVGUUAL-UHFFFAOYSA-L ditert-butyl(cyclopenta-1,3-dien-1-yl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.CC(C)(C)P(C(C)(C)C)C1=CC=C[CH-]1.CC(C)(C)P(C(C)(C)C)C1=CC=C[CH-]1 LZWLLMFYVGUUAL-UHFFFAOYSA-L 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 4
- 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 238000004020 luminiscence type Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- GQJCAQADCPTHKN-UHFFFAOYSA-N methyl 2,2-difluoro-2-fluorosulfonylacetate Chemical compound COC(=O)C(F)(F)S(F)(=O)=O GQJCAQADCPTHKN-UHFFFAOYSA-N 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 125000002950 monocyclic group Chemical group 0.000 description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 4
- 229960005080 warfarin Drugs 0.000 description 4
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 4
- 125000006559 (C1-C3) alkylamino group Chemical group 0.000 description 3
- 125000006592 (C2-C3) alkenyl group Chemical group 0.000 description 3
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 3
- 108700022174 Drosophila Son of Sevenless Proteins 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 101150105104 Kras gene Proteins 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 239000006143 cell culture medium Substances 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 108010021848 cyclosomatostatin Proteins 0.000 description 3
- 229910052805 deuterium Inorganic materials 0.000 description 3
- 125000004494 ethyl ester group Chemical group 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- MUJIDPITZJWBSW-UHFFFAOYSA-N palladium(2+) Chemical compound [Pd+2] MUJIDPITZJWBSW-UHFFFAOYSA-N 0.000 description 3
- 125000003386 piperidinyl group Chemical group 0.000 description 3
- 238000007747 plating Methods 0.000 description 3
- 235000011056 potassium acetate Nutrition 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 102000016914 ras Proteins Human genes 0.000 description 3
- 239000011535 reaction buffer Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- 238000000967 suction filtration Methods 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 2
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- 101100404726 Arabidopsis thaliana NHX7 gene Proteins 0.000 description 2
- 238000011729 BALB/c nude mouse Methods 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 125000000041 C6-C10 aryl group Chemical group 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 206010069755 K-ras gene mutation Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 241000238633 Odonata Species 0.000 description 2
- 241000233805 Phoenix Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 102000001788 Proto-Oncogene Proteins c-raf Human genes 0.000 description 2
- 108010029869 Proto-Oncogene Proteins c-raf Proteins 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 101150040459 RAS gene Proteins 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 108700022176 SOS1 Proteins 0.000 description 2
- 102000057028 SOS1 Human genes 0.000 description 2
- 101100197320 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) RPL35A gene Proteins 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 101150100839 Sos1 gene Proteins 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 238000012200 cell viability kit Methods 0.000 description 2
- 238000002038 chemiluminescence detection Methods 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 2
- SNRCKKQHDUIRIY-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloromethane;dichloropalladium;iron(2+) Chemical compound [Fe+2].ClCCl.Cl[Pd]Cl.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 SNRCKKQHDUIRIY-UHFFFAOYSA-L 0.000 description 2
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- SXZIXHOMFPUIRK-UHFFFAOYSA-N diphenylmethanimine Chemical compound C=1C=CC=CC=1C(=N)C1=CC=CC=C1 SXZIXHOMFPUIRK-UHFFFAOYSA-N 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- ODCCJTMPMUFERV-UHFFFAOYSA-N ditert-butyl carbonate Chemical compound CC(C)(C)OC(=O)OC(C)(C)C ODCCJTMPMUFERV-UHFFFAOYSA-N 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- VFRSADQPWYCXDG-LEUCUCNGSA-N ethyl (2s,5s)-5-methylpyrrolidine-2-carboxylate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCOC(=O)[C@@H]1CC[C@H](C)N1 VFRSADQPWYCXDG-LEUCUCNGSA-N 0.000 description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 2
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000011698 potassium fluoride Substances 0.000 description 2
- 235000003270 potassium fluoride Nutrition 0.000 description 2
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 2
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 108010014186 ras Proteins Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 102200006538 rs121913530 Human genes 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 125000003003 spiro group Chemical group 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- TYFQFVWCELRYAO-UHFFFAOYSA-N suberic acid Chemical compound OC(=O)CCCCCCC(O)=O TYFQFVWCELRYAO-UHFFFAOYSA-N 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 238000002877 time resolved fluorescence resonance energy transfer Methods 0.000 description 2
- WLPUWLXVBWGYMZ-UHFFFAOYSA-N tricyclohexylphosphine Chemical compound C1CCCCC1P(C1CCCCC1)C1CCCCC1 WLPUWLXVBWGYMZ-UHFFFAOYSA-N 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 1
- NWNOWCGAHDFNFJ-RUCXOUQFSA-N (2s)-2,5-bis(azanyl)-5-oxidanylidene-pentanoic acid Chemical compound OC(=O)[C@@H](N)CCC(N)=O.OC(=O)[C@@H](N)CCC(N)=O NWNOWCGAHDFNFJ-RUCXOUQFSA-N 0.000 description 1
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 description 1
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 1
- IDPURXSQCKYKIJ-UHFFFAOYSA-N 1-(4-methoxyphenyl)methanamine Chemical compound COC1=CC=C(CN)C=C1 IDPURXSQCKYKIJ-UHFFFAOYSA-N 0.000 description 1
- MOHYOXXOKFQHDC-UHFFFAOYSA-N 1-(chloromethyl)-4-methoxybenzene Chemical compound COC1=CC=C(CCl)C=C1 MOHYOXXOKFQHDC-UHFFFAOYSA-N 0.000 description 1
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical group CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 1
- PAJALBWYDSQWAV-UHFFFAOYSA-N 1-isocyanosulfonyl-4-methylbenzene Chemical compound CC1=CC=C(S(=O)(=O)[N+]#[C-])C=C1 PAJALBWYDSQWAV-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 description 1
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- XSHFQVMIVZWTQL-UHFFFAOYSA-N 2,3,4-trimethylpentan-3-yl acetate Chemical compound CC(C)C(C)(C(C)C)OC(C)=O XSHFQVMIVZWTQL-UHFFFAOYSA-N 0.000 description 1
- PEMUGDMSUDYLHU-ZEQRLZLVSA-N 2-[(2S)-4-[7-(8-chloronaphthalen-1-yl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile Chemical compound ClC=1C=CC=C2C=CC=C(C=12)N1CC=2N=C(N=C(C=2CC1)N1C[C@@H](N(CC1)C(C(=C)F)=O)CC#N)OC[C@H]1N(CCC1)C PEMUGDMSUDYLHU-ZEQRLZLVSA-N 0.000 description 1
- NNWFSRBWMOZDAK-UHFFFAOYSA-N 2-[2-(carboxymethyl)-3-iodophenyl]acetic acid Chemical compound OC(=O)CC1=CC=CC(I)=C1CC(O)=O NNWFSRBWMOZDAK-UHFFFAOYSA-N 0.000 description 1
- 125000004174 2-benzimidazolyl group Chemical group [H]N1C(*)=NC2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- KDFDOINBXBEOLZ-UHFFFAOYSA-N 2-phenylpropan-2-amine Chemical compound CC(C)(N)C1=CC=CC=C1 KDFDOINBXBEOLZ-UHFFFAOYSA-N 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- GWGZFNRFNIXCGH-UHFFFAOYSA-N 4-nitro-2-(trifluoromethyl)benzenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1C(F)(F)F GWGZFNRFNIXCGH-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical group [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 description 1
- ODGIMMLDVSWADK-UHFFFAOYSA-N 4-trifluoromethylaniline Chemical compound NC1=CC=C(C(F)(F)F)C=C1 ODGIMMLDVSWADK-UHFFFAOYSA-N 0.000 description 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 1
- CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 description 1
- 125000006164 6-membered heteroaryl group Chemical group 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- KTPJSJOTUGLYAS-UHFFFAOYSA-N CC(C)(C)[P] Chemical compound CC(C)(C)[P] KTPJSJOTUGLYAS-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 102100029974 GTPase HRas Human genes 0.000 description 1
- 102100039788 GTPase NRas Human genes 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- 101000584633 Homo sapiens GTPase HRas Proteins 0.000 description 1
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 241000713862 Moloney murine sarcoma virus Species 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 101100330292 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cys-12 gene Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 208000008900 Pancreatic Ductal Carcinoma Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102100033479 RAF proto-oncogene serine/threonine-protein kinase Human genes 0.000 description 1
- 101710141955 RAF proto-oncogene serine/threonine-protein kinase Proteins 0.000 description 1
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- DRUIESSIVFYOMK-UHFFFAOYSA-N Trichloroacetonitrile Chemical compound ClC(Cl)(Cl)C#N DRUIESSIVFYOMK-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- PNDPGZBMCMUPRI-XXSWNUTMSA-N [125I][125I] Chemical compound [125I][125I] PNDPGZBMCMUPRI-XXSWNUTMSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229940124988 adagrasib Drugs 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- SOIFLUNRINLCBN-UHFFFAOYSA-N ammonium thiocyanate Chemical compound [NH4+].[S-]C#N SOIFLUNRINLCBN-UHFFFAOYSA-N 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002022 anti-cellular effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 125000003943 azolyl group Chemical group 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- QABCGOSYZHCPGN-UHFFFAOYSA-N chloro(dimethyl)silicon Chemical compound C[Si](C)Cl QABCGOSYZHCPGN-UHFFFAOYSA-N 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- JNGZXGGOCLZBFB-IVCQMTBJSA-N compound E Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C(C=2C=CC=CC=2)=N1)=O)C(=O)CC1=CC(F)=CC(F)=C1 JNGZXGGOCLZBFB-IVCQMTBJSA-N 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 1
- 238000012364 cultivation method Methods 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- ORBBTCHHNMWMCP-UHFFFAOYSA-K cycloocta-1,5-diene trichloroiridium Chemical class [Ir](Cl)(Cl)Cl.C1=CCCC=CCC1 ORBBTCHHNMWMCP-UHFFFAOYSA-K 0.000 description 1
- AQEFLFZSWDEAIP-UHFFFAOYSA-N di-tert-butyl ether Chemical compound CC(C)(C)OC(C)(C)C AQEFLFZSWDEAIP-UHFFFAOYSA-N 0.000 description 1
- ZOCHARZZJNPSEU-UHFFFAOYSA-N diboron Chemical compound B#B ZOCHARZZJNPSEU-UHFFFAOYSA-N 0.000 description 1
- LFLVWJRUOWNNAC-UHFFFAOYSA-N dicyclohexyl-[2-phenyl-1,3,5-tri(propan-2-yl)cyclohexa-2,4-dien-1-yl]phosphane Chemical group C1CCCCC1P(C1CCCCC1)C1(C(C)C)CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1 LFLVWJRUOWNNAC-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- NZZFYRREKKOMAT-UHFFFAOYSA-N diiodomethane Chemical compound ICI NZZFYRREKKOMAT-UHFFFAOYSA-N 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- JMVOCSLPMGHXPG-UHFFFAOYSA-N dipotassium;dioxido(dioxo)osmium Chemical compound [K+].[K+].[O-][Os]([O-])(=O)=O JMVOCSLPMGHXPG-UHFFFAOYSA-N 0.000 description 1
- 125000005883 dithianyl group Chemical group 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 1
- IRXSLJNXXZKURP-UHFFFAOYSA-N fluorenylmethyloxycarbonyl chloride Chemical compound C1=CC=C2C(COC(=O)Cl)C3=CC=CC=C3C2=C1 IRXSLJNXXZKURP-UHFFFAOYSA-N 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- FVIZARNDLVOMSU-UHFFFAOYSA-N ginsenoside K Natural products C1CC(C2(CCC3C(C)(C)C(O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O FVIZARNDLVOMSU-UHFFFAOYSA-N 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229960000789 guanidine hydrochloride Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- USZLCYNVCCDPLQ-UHFFFAOYSA-N hydron;n-methoxymethanamine;chloride Chemical compound Cl.CNOC USZLCYNVCCDPLQ-UHFFFAOYSA-N 0.000 description 1
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- OCVXZQOKBHXGRU-UHFFFAOYSA-N iodine(1+) Chemical group [I+] OCVXZQOKBHXGRU-UHFFFAOYSA-N 0.000 description 1
- 229940044173 iodine-125 Drugs 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- OWFXIOWLTKNBAP-UHFFFAOYSA-N isoamyl nitrite Chemical compound CC(C)CCON=O OWFXIOWLTKNBAP-UHFFFAOYSA-N 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000007422 luminescence assay Methods 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- RMGJCSHZTFKPNO-UHFFFAOYSA-M magnesium;ethene;bromide Chemical compound [Mg+2].[Br-].[CH-]=C RMGJCSHZTFKPNO-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 125000004572 morpholin-3-yl group Chemical group N1C(COCC1)* 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 239000010413 mother solution Substances 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- UVEWQKMPXAHFST-UHFFFAOYSA-N n,1-diphenylmethanimine Chemical compound C=1C=CC=CC=1C=NC1=CC=CC=C1 UVEWQKMPXAHFST-UHFFFAOYSA-N 0.000 description 1
- ULWOJODHECIZAU-UHFFFAOYSA-N n,n-diethylpropan-2-amine Chemical compound CCN(CC)C(C)C ULWOJODHECIZAU-UHFFFAOYSA-N 0.000 description 1
- RIVIDPPYRINTTH-UHFFFAOYSA-N n-ethylpropan-2-amine Chemical compound CCNC(C)C RIVIDPPYRINTTH-UHFFFAOYSA-N 0.000 description 1
- 125000003506 n-propoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- XTUSEBKMEQERQV-UHFFFAOYSA-N propan-2-ol;hydrate Chemical compound O.CC(C)O XTUSEBKMEQERQV-UHFFFAOYSA-N 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000006920 protein precipitation Effects 0.000 description 1
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 108700042226 ras Genes Proteins 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 102200006531 rs121913529 Human genes 0.000 description 1
- 229910052707 ruthenium Inorganic materials 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- YPNVIBVEFVRZPJ-UHFFFAOYSA-L silver sulfate Chemical compound [Ag+].[Ag+].[O-]S([O-])(=O)=O YPNVIBVEFVRZPJ-UHFFFAOYSA-L 0.000 description 1
- 229910000367 silver sulfate Inorganic materials 0.000 description 1
- 238000004467 single crystal X-ray diffraction Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- NXQKSXLFSAEQCZ-SFHVURJKSA-N sotorasib Chemical compound FC1=CC2=C(N(C(N=C2N2[C@H](CN(CC2)C(C=C)=O)C)=O)C=2C(=NC=CC=2C)C(C)C)N=C1C1=C(C=CC=C1O)F NXQKSXLFSAEQCZ-SFHVURJKSA-N 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 1
- RUPAXCPQAAOIPB-UHFFFAOYSA-N tert-butyl formate Chemical compound CC(C)(C)OC=O RUPAXCPQAAOIPB-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 125000004192 tetrahydrofuran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- HQFTZNVQVRRDLN-UHFFFAOYSA-M tetramethylazanium;fluoride;tetrahydrate Chemical compound O.O.O.O.[F-].C[N+](C)(C)C HQFTZNVQVRRDLN-UHFFFAOYSA-M 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000002053 thietanyl group Chemical group 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 230000004222 uncontrolled growth Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Definitions
- the present invention relates to a class of pyrimidoaromatic compounds, in particular to a compound represented by formula (II) or a pharmaceutically acceptable salt thereof.
- RAS oncogene mutations are the most common activating mutations in human cancers, present in about 30% of human tumors.
- the RAS gene family includes three subtypes (KRAS, HRAS, and NRAS), of which 85% of RAS-driven cancers are caused by mutations in the KRAS subtype.
- KRAS is a murine sarcoma virus oncogene and an important member of the RAS protein. KRAS is like a molecular switch, once it is turned on, it will activate a variety of division and proliferation factors, such as c-RAF, PI3K and so on. Under normal circumstances, KRAS binds to GTP, cuts off a phosphate group at the end of GTP, and turns it into GDP. After GTP is turned into GDP, KRAS is closed. Under normal circumstances, KRAS can regulate the path of cell growth; after KRAS gene mutation, KRAS protein continues to remain activated, and can independently transmit growth and proliferation signals to downstream pathways independent of upstream growth factor receptor signals, resulting in uncontrolled growth and proliferation. Cell growth and tumor progression.
- KRAS mutations are commonly found in solid tumors such as lung adenocarcinoma, pancreatic ductal carcinoma, and colorectal cancer. In KRAS-mutant tumors, 80% of oncogenic mutations occurred at codon 12, with the most common mutations including: p.G12D (41%), p.G12V (28%), and p.G12C (14%). At the same time, whether the KRAS gene has mutation is also an important indicator of tumor prognosis.
- KRAS G12C small molecules that directly target KRAS mutations are mainly concentrated in the field of KRAS G12C , including Amgen's AMG510 and Mirati Therapeutics' MRTX849. Clinical results show that these two compounds have shown good therapeutic effects on KRAS G12C- mutated tumor patients. . However, no KRAS G12D small molecule has entered the clinical research stage so far, and there is a huge unmet need for KRAS G12D mutation inhibitors in clinical practice.
- the present invention provides a compound represented by formula (II) or a pharmaceutically acceptable salt thereof
- L 1 is selected from -CH 2 - and a bond
- Ring A is selected from said optionally substituted with 1, 2 or 3 Ra ;
- T 1 is selected from CH 2 , NH and O;
- T 2 is selected from CH and N;
- T 3 and T 4 are independently selected from CH 2 and NH;
- n, p and x are each independently selected from 0, 1 or 2;
- r, v and w are each independently selected from 1 or 2;
- q, s and u are each independently selected from 1, 2 or 3;
- R 1 is selected from C 6-10 aryl and 5-10 membered heteroaryl, the C 6-10 aryl and 5-10 membered heteroaryl are optionally surrounded by 1, 2, 3, 4 or 5 R b replace;
- R 2 is selected from H, F, Cl, CN, NH 2 , C 1-3 alkyl and C 1-3 alkoxy, and said C 1-3 alkyl and C 1-3 alkoxy are optionally , 2 or 3 halogen substitutions;
- R 3 is selected from H, F, Cl, C 1-3 alkyl, C 1-3 alkoxy, C 2-4 alkenyl and cyclopropyl, the C 1-3 alkyl, C 1-3 alkane Oxy, C 2-4 alkenyl and cyclopropyl are optionally substituted with 1, 2 or 3 halogens;
- R4 is selected from 4-8 membered heterocycloalkyl and The 4-8 membered heterocycloalkyl and optionally substituted with 1, 2 or 3 R e ; structural unit selected from 5-6 membered heterocycloalkenyl;
- each R a is independently selected from F, Cl, Br, I and CH 3 ;
- Each R b is independently selected from F, Cl, Br, I, OH, NH 2 , CN, C 1-3 alkyl, C 1-3 alkoxy, C 2-4 alkenyl and C 2-4 alkyne base, the C 1-3 alkyl, C 1-3 alkoxy, C 2-4 alkenyl and C 2-4 alkynyl are optionally substituted with 1, 2 or 3 halogens;
- Each R e is independently selected from H, F, Cl, Br, OH, CN, C 1-3 alkyl, C 1-3 alkoxy and -C 1-3 alkyl-O-CO-C 1- 3 Alkylamino.
- the compound, or a pharmaceutically acceptable salt thereof, wherein Ring A is selected from Other variables are as defined in the present invention.
- each R b is independently selected from F, Cl, OH, NH 2 , CN, CH 3 , CF 3 , CH 2 CH 3 and -C ⁇ CH, and other variables are as in the present invention defined.
- the R 1 is selected from phenyl, pyridyl, naphthyl, quinolyl, benzothiazolyl and benzothienyl, the phenyl, pyridyl, naphthyl, quinoline , benzothiazolyl and benzothienyl are optionally substituted with 1, 2 , 3, 4 or 5 R, other variables are as defined in the present invention
- the R 1 is selected from Other variables are as defined in the present invention.
- the R 1 is selected from Other variables are as defined in the present invention.
- the R 2 is selected from H, F, Cl, CH 3 and OCH 3 , and the CH 3 and OCH 3 are optionally substituted with 1, 2 or 3 halogens, and other variables are as in the present invention defined.
- said R2 is selected from H, F, Cl , OCH3 and OCHF2 , and other variables are as defined herein.
- each Re is independently selected from H, F, Cl , Br, OH, CN, CH3 , CH2CH3 , OCH3 , and Other variables are as defined in the present invention.
- said R4 is selected from tetrahydropyrrolyl and hexahydro - 1H-pyrrolizinyl, said tetrahydropyrrolyl and hexahydro-1H-pyrrolizinyl being separated by 1, 2 or 3 R e substitutions, other variables are as defined in the present invention.
- the R4 is selected from Other variables are as defined in the present invention.
- the present invention provides a compound represented by formula (II) or a pharmaceutically acceptable salt thereof
- L 1 is selected from -CH 2 - and a bond
- Ring A is selected from said optionally substituted with 1, 2 or 3 Ra ;
- T 1 is selected from CH 2 , NH and O;
- T 2 is selected from CH and N;
- T 3 and T 4 are independently selected from CH 2 and NH;
- n, p and x are each independently selected from 0, 1 or 2;
- r, v and w are each independently selected from 1 or 2;
- q, s and u are each independently selected from 1, 2 or 3;
- R 1 is selected from C 6-10 aryl and 5-10 membered heteroaryl, the C 6-10 aryl and 5-10 membered heteroaryl are optionally surrounded by 1, 2, 3, 4 or 5 R b replace;
- R 2 is selected from H, F, Cl, CN, NH 2 , C 1-3 alkyl and C 1-3 alkoxy, and said C 1-3 alkyl and C 1-3 alkoxy are optionally , 2 or 3 halogen substitutions;
- R 3 is selected from H, F, Cl, C 1-3 alkyl, C 1-3 alkoxy, C 2-4 alkenyl and cyclopropyl, the C 1-3 alkyl, C 1-3 alkane Oxy, C 2-4 alkenyl and cyclopropyl are optionally substituted with 1, 2 or 3 halogens;
- R4 is selected from 4-8 membered heterocycloalkyl and The 4-8 membered heterocycloalkyl and optionally substituted with 1, 2 or 3 R e ; structural unit selected from 5-6 membered heterocycloalkenyl;
- each R a is independently selected from F, Cl, Br, I and CH 3 ;
- Each R b is independently selected from F, Cl, Br, I, OH, NH 2 , CN, C 1-3 alkyl, C 1-3 alkoxy, C 2-4 alkenyl and C 2-4 alkyne base, the C 1-3 alkyl, C 1-3 alkoxy, C 2-4 alkenyl and C 2-4 alkynyl are optionally substituted with 1, 2 or 3 halogens;
- Each R e is independently selected from H, F, Cl, Br, OH, CN, C 1-3 alkyl, C 1-3 alkoxy and -C 1-3 alkyl-O-CO-C 1- 3 Alkylamino.
- the compound, or a pharmaceutically acceptable salt thereof, wherein Ring A is selected from Other variables are as defined in the present invention.
- the compound, or a pharmaceutically acceptable salt thereof, wherein Ring A is selected from Other variables are as defined in the present invention.
- each R b is independently selected from F, OH, NH 2 , CN, CH 3 , CF 3 , CH 2 CH 3 and -C ⁇ CH, and other variables are as defined in the present invention .
- the R 1 is selected from the group consisting of phenyl, naphthyl, benzothiazolyl and benzothienyl, said phenyl, naphthyl, benzothiazolyl and benzothienyl optionally being 1, 2, 3, 4 or 5 R b substitutions, other variables are as defined in the present invention
- the R 1 is selected from Other variables are as defined in the present invention.
- the R 1 is selected from Other variables are as defined in the present invention.
- the R 1 is selected from Other variables are as defined in the present invention.
- the R 1 is selected from Other variables are as defined in the present invention.
- the R 1 is selected from Other variables are as defined in the present invention.
- the R 2 is selected from H, F, Cl, CH 3 and OCH 3 , and the CH 3 and OCH 3 are optionally substituted with 1, 2 or 3 halogens, and other variables are as in the present invention defined.
- said R2 is selected from H, F, Cl , OCH3 and OCHF2 , and other variables are as defined herein.
- each Re is independently selected from H, F, Cl , Br, OH, CN, CH3 , CH2CH3 , OCH3 , and Other variables are as defined in the present invention.
- said R4 is selected from tetrahydropyrrolyl and hexahydro - 1H-pyrrolizinyl, said tetrahydropyrrolyl and hexahydro-1H-pyrrolizinyl being separated by 1, 2 or 3 R e substitutions, other variables are as defined in the present invention.
- the R4 is selected from Other variables are as defined in the present invention.
- the present invention provides a compound represented by formula (II) or a pharmaceutically acceptable salt thereof
- L 1 is selected from -CH 2 - and a bond
- Ring A is selected from said optionally substituted with 1, 2 or 3 Ra ;
- T 1 is selected from CH 2 , NH and O;
- T 2 is selected from CH and N;
- T 3 and T 4 are independently selected from CH 2 and NH;
- n, p and x are each independently selected from 0, 1 or 2;
- r, v and w are each independently selected from 1 or 2;
- q, s and u are each independently selected from 1, 2 or 3;
- R 1 is selected from C 6-10 aryl and 5-10 membered heteroaryl, the C 6-10 aryl and 5-10 membered heteroaryl are optionally surrounded by 1, 2, 3, 4 or 5 R b replace;
- R 2 is selected from H, F, Cl, CN, NH 2 , C 1-3 alkyl and C 1-3 alkoxy, and said C 1-3 alkyl and C 1-3 alkoxy are optionally , 2 or 3 R c substitutions;
- R 3 is selected from H, F, Cl, C 1-3 alkyl, C 1-3 alkoxy, C 2-4 alkenyl and cyclopropyl, the C 1-3 alkyl, C 1-3 alkane Oxy, C 2-4 alkenyl and cyclopropyl are optionally substituted with 1, 2 or 3 R d ;
- R4 is selected from 4-8 membered heterocycloalkyl and The 4-8 membered heterocycloalkyl and optionally substituted with 1, 2 or 3 R e ; structural unit selected from 5-6 membered heterocycloalkenyl;
- each R a is independently selected from F, Cl, Br, I and CH 3 ;
- Each R b is independently selected from F, Cl, Br, I, OH, NH 2 , CN, C 1-3 alkyl, C 1-3 alkoxy, C 2-4 alkenyl and C 2-4 alkyne base, the C 1-3 alkyl, C 1-3 alkoxy, C 2-4 alkenyl and C 2-4 alkynyl are optionally substituted with 1, 2 or 3 R;
- each R c is independently selected from F, Cl, Br and I;
- each R d is independently selected from F, Cl, Br and I;
- Each R e is independently selected from H, F, Cl, Br, OH, CN, C 1-3 alkyl, C 1-3 alkoxy and -C 1-3 alkyl-O-CO-C 1- 3 alkylamino;
- Each R is independently selected from F, Cl, Br, I.
- the compound, or a pharmaceutically acceptable salt thereof, wherein Ring A is selected from Other variables are as defined in the present invention.
- each R b is independently selected from F, OH, NH 2 , CH 3 , CF 3 , CH 2 CH 3 and -C ⁇ CH, and other variables are as defined herein.
- the R 1 is selected from Other variables are as defined in the present invention.
- the R 1 is selected from Other variables are as defined in the present invention.
- the R 1 is selected from Other variables are as defined in the present invention.
- the R 1 is selected from Other variables are as defined in the present invention.
- the R 2 is selected from H, F, CH 3 and OCH 3 , and the CH 3 and OCH 3 are optionally substituted with 1, 2 or 3 R c , and other variables are as defined in the present invention definition.
- said R2 is selected from H, F, OCH3 and OCHF2 , and other variables are as defined herein.
- each Re is independently selected from H, F, Cl , Br, OH, CN, CH3 , CH2CH3 , CH2CF3 , OCH3 , OCF3 , and Other variables are as defined in the present invention.
- each Re is independently selected from H, F, Cl , Br, OH, CN, CH3 , CH2CH3 , OCH3 , and Other variables are as defined in the present invention.
- said R4 is selected from tetrahydropyrrolyl and hexahydro - 1H-pyrrolizinyl, said tetrahydropyrrolyl and hexahydro-1H-pyrrolizinyl being separated by 1, 2 or 3 R e substitutions, other variables are as defined in the present invention.
- the R4 is selected from Other variables are as defined in the present invention.
- the present invention provides a compound represented by formula (I) or a pharmaceutically acceptable salt thereof
- Ring A is selected from said optionally substituted with 1, 2 or 3 Ra ;
- T 1 , T 2 , T 3 and T 4 are each independently selected from CH and N;
- n, p and x are each independently selected from 0, 1 or 2;
- r, v and w are each independently selected from 1 or 2;
- q, s and u are each independently selected from 1, 2 or 3;
- R 1 is selected from phenyl and naphthyl optionally substituted with 1, 2, 3, 4 or 5 R b ;
- R 2 is selected from H, F, Cl, CN, NH 2 , C 1-3 alkyl and C 1-3 alkoxy, and said C 1-3 alkyl and C 1-3 alkoxy are optionally , 2 or 3 R c substitutions;
- R 3 is selected from H, F, Cl, C 1-3 alkyl, C 1-3 alkoxy, C 2-4 alkenyl and cyclopropyl, the C 1-3 alkyl, C 1-3 alkane Oxy, C 2-4 alkenyl and cyclopropyl are optionally substituted with 1, 2 or 3 R d ;
- each R a is independently selected from F, Cl, Br, I and CH 3 ;
- each R b is independently selected from F, Cl, Br, I, OH, NH 2 , CN, CH 3 , CF 3 and OCH 3 ;
- each R c is independently selected from F, Cl, Br and I;
- Each R d is independently selected from F, Cl, Br and I.
- the compound, or a pharmaceutically acceptable salt thereof, wherein Ring A is selected from Other variables are as defined in the present invention.
- the R 1 is selected from Other variables are as defined in the present invention.
- the R 2 is selected from H, F, CH 3 and OCH 3 , and the CH 3 and OCH 3 are optionally substituted with 1, 2 or 3 R c , and other variables are as defined in the present invention definition.
- said R2 is selected from H, F, OCH3 and OCHF2 , and other variables are as defined herein.
- the compound, or a pharmaceutically acceptable salt thereof is selected from
- Ring A, R 1 , R 2 and R 3 are as defined in the present invention.
- the compound, or a pharmaceutically acceptable salt thereof is selected from
- T 6 is selected from CH and N;
- R 1 , R 2 , R 3 and Re are as defined in the present invention.
- the compound, or a pharmaceutically acceptable salt thereof is selected from
- T 6 , R 1 , R 2 and R 3 are as defined in the present invention.
- the compound, or a pharmaceutically acceptable salt thereof is selected from
- T 5 and T 6 are each independently selected from CH and N;
- y is selected from 0, 1, 2, 3, 4 and 5;
- R b is as defined in the present invention.
- the compound, or a pharmaceutically acceptable salt thereof is selected from
- T 6 is selected from CH and N;
- R 1 , R 2 and R 3 are as defined in the invention.
- the compound, or a pharmaceutically acceptable salt thereof is selected from
- T 6 is selected from CH and N;
- R 2 and R 3 are as defined in the invention.
- R b1 , R b2 , R b3 , R b4 , R b5 , R b6 , R b7 , R b8 , R b9 , R b10 and R b11 is independently selected from H, F, Cl, Br, I, OH, NH 2 , CN, C 1-3 alkyl, C 1-3 alkoxy, C 2-4 alkenyl and C 2-4 alkynyl, the C 1-3 alkyl, C 1-3 alkoxy , C2-4alkenyl and C2-4alkynyl are optionally substituted with 1, 2 or 3 halogens.
- each of said R b1 , R b2 , R b3 , R b4 , R b5 , R b6 , R b7 , R b8 , R b9 , R b10 and R b11 is independently selected from F, Cl, OH, NH2 , CN, CH3 , CF3 , CH2CH3 and -C ⁇ CH , other variables are as defined in the present invention.
- the present invention also provides a compound of the following formula or a pharmaceutically acceptable salt thereof, which is selected from the group consisting of
- the compound, or a pharmaceutically acceptable salt thereof is selected from
- the compound, or a pharmaceutically acceptable salt thereof is selected from
- the present invention also provides the compound or a pharmaceutically acceptable salt thereof, and its application in the preparation of a medicament for treating KRAS G12D mutation-related tumors.
- the tumors refer to colorectal cancer and pancreatic cancer.
- the present invention also provides following synthetic method:
- R 2 and R 3 are as defined in the present invention.
- R 2 and R 3 are as defined in the present invention.
- R 2 is as defined in the present invention.
- R 2 is as defined in the present invention.
- Test Method 2 Anticellular Proliferative Effects of Compounds in Tumor Cell Lines AsPC-1 and GP2D
- RPMI 1640 fetal bovine serum
- FBS fetal bovine serum
- Antibiotic-antimycotic antibiotic-antifungal
- L-glutamine L-glutamine
- DMSO dimethyl sulfoxide
- the tumor cell lines were cultured in a 37°C, 5% CO2 incubator according to the culture conditions indicated in the culture method. Periodically passaged, cells in logarithmic growth phase were taken for plating.
- the plates were incubated overnight in an incubator at 37°C, 5% CO2 , and 100% relative humidity.
- the solution in the ULA plate was then transferred to a black bottom plate (#655090) and left at room temperature for 25 minutes to stabilize the luminescent signal.
- Luminescence signals were detected on a 2104EnVision plate reader.
- IR(%) (1 ⁇ (RLU compound ⁇ RLU blank control)/(RLU vehicle control ⁇ RLU blank control)*100%.
- the inhibition rates of different concentrations of compounds were calculated in Excel, and then the GraphPad Prism software was used to plot the inhibition curves and calculate the relevant parameters, including the minimum inhibition rate, the maximum inhibition rate and IC 50 .
- the compound of the present invention has good binding effect and inhibitory effect on KRAS G12D protein, can effectively inhibit the downstream signal p-ERK, has good cell proliferation inhibitory activity on KRAS G12D mutant cells, and has a significant inhibitory effect on tumors.
- the compounds of the present invention have good pharmacokinetic properties.
- the term "pharmaceutically acceptable” refers to those compounds, materials, compositions and/or dosage forms that, within the scope of sound medical judgment, are suitable for use in contact with human and animal tissue , without excessive toxicity, irritation, allergic reactions or other problems or complications, commensurate with a reasonable benefit/risk ratio.
- salts refers to salts of the compounds of the present invention, prepared from compounds with specific substituents discovered by the present invention and relatively non-toxic acids or bases.
- base addition salts can be obtained by contacting such compounds with a sufficient amount of base in neat solution or in a suitable inert solvent.
- Pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amine or magnesium salts or similar salts.
- acid addition salts can be obtained by contacting such compounds with a sufficient amount of acid in neat solution or in a suitable inert solvent.
- Examples of pharmaceutically acceptable acid addition salts include inorganic acid salts including, for example, hydrochloric acid, hydrobromic acid, nitric acid, carbonic acid, bicarbonate, phosphoric acid, monohydrogen phosphate, dihydrogen phosphate, sulfuric acid, Hydrogen sulfate, hydroiodic acid, phosphorous acid, etc.; and organic acid salts including, for example, acetic acid, propionic acid, isobutyric acid, maleic acid, malonic acid, benzoic acid, succinic acid, suberic acid, Similar acids such as fumaric, lactic, mandelic, phthalic, benzenesulfonic, p-toluenesulfonic, citric, tartaric, and methanesulfonic acids; also include salts of amino acids such as arginine, etc. , and salts of organic acids such as glucuronic acid. Certain specific compounds of the present invention contain both basic and acidic functional groups and thus can be converted into either base
- the pharmaceutically acceptable salts of the present invention can be synthesized from the acid or base containing parent compound by conventional chemical methods. Generally, such salts are prepared by reacting the free acid or base form of these compounds with a stoichiometric amount of the appropriate base or acid in water or an organic solvent or a mixture of the two.
- the compounds of the present invention may exist in specific geometric or stereoisomeric forms.
- the present invention contemplates all such compounds, including cis and trans isomers, (-)- and (+)-enantiomers, (R)- and (S)-enantiomers, diastereomers isomers, (D)-isomers, (L)-isomers, and racemic mixtures thereof and other mixtures, such as enantiomerically or diastereomerically enriched mixtures, all of which belong to this within the scope of the invention.
- Additional asymmetric carbon atoms may be present in substituents such as alkyl. All such isomers, as well as mixtures thereof, are included within the scope of the present invention.
- the compounds of the present invention may contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute the compound.
- compounds can be labeled with radioisotopes, such as tritium ( 3 H), iodine-125 ( 125 I) or C-14 ( 14 C).
- deuterated drugs can be formed by replacing hydrogen with deuterium, and the bonds formed by deuterium and carbon are stronger than those formed by ordinary hydrogen and carbon. Compared with non-deuterated drugs, deuterated drugs can reduce toxic side effects and increase drug stability. , enhance the efficacy, prolong the biological half-life of drugs and other advantages. All transformations of the isotopic composition of the compounds of the present invention, whether radioactive or not, are included within the scope of the present invention.
- substituted means that any one or more hydrogen atoms on a specified atom are replaced by a substituent, which may include deuterium and hydrogen variants, as long as the valence of the specified atom is normal and the substituted compound is stable.
- oxygen it means that two hydrogen atoms are substituted. Oxygen substitution does not occur on aromatic groups.
- optionally substituted means that it may or may not be substituted, and unless otherwise specified, the type and number of substituents may be arbitrary on a chemically achievable basis.
- any variable eg, R
- its definition in each case is independent.
- the group may optionally be substituted with up to two Rs, with independent options for R in each case.
- combinations of substituents and/or variants thereof are permissible only if such combinations result in stable compounds.
- linking group When the number of a linking group is 0, such as -(CRR) 0 -, it means that the linking group is a single bond.
- linking groups When the listed linking groups do not indicate the direction of attachment, they are read from left to right as shown in the plane, for example,
- the linking group L in the middle is -MW-, at this time -MW- connects ring A and ring B in the same direction as the reading order from left to right.
- Combinations of the linking groups, substituents and/or variants thereof are permissible only if such combinations result in stable compounds.
- any one or more sites in the group can be linked to other groups by chemical bonds.
- connection method of the chemical bond is not located, and there is an H atom at the linkable site, when the chemical bond is connected, the number of H atoms at the site will be correspondingly reduced with the number of chemical bonds connected to the corresponding valence. the group.
- the chemical bond connecting the site to other groups can be represented by straight solid line bonds straight dotted key or wavy lines express.
- a straight solid bond in -OCH 3 indicates that it is connected to other groups through the oxygen atom in this group;
- the straight dashed bond in the group indicates that it is connected to other groups through the two ends of the nitrogen atom in the group;
- the wavy line in the phenyl group indicates that it is connected to other groups through the 1 and 2 carbon atoms in the phenyl group;
- Indicates that any linkable site on the naphthalene[2,3-d]isoxazolyl group can be connected to other groups through a chemical bond, at least including These 7 ways to connect.
- halogen or halogen by itself or as part of another substituent means a fluorine (F), chlorine (Cl), bromine (Br) or iodine (I) atom.
- C 1-3 alkyl is used to denote a straight or branched chain saturated hydrocarbon group consisting of 1 to 3 carbon atoms.
- the C 1-3 alkyl group includes C 1-2 and C 2-3 alkyl groups, etc.; it can be monovalent (eg methyl), divalent (eg methylene) or multivalent (eg methine) .
- Examples of C1-3 alkyl groups include, but are not limited to, methyl (Me), ethyl (Et), propyl (including n-propyl and isopropyl), and the like.
- C1-3alkoxy refers to those alkyl groups containing 1 to 3 carbon atoms attached to the remainder of the molecule through an oxygen atom.
- the C 1-3 alkoxy group includes C 1-2 , C 2-3 , C 3 and C 2 alkoxy and the like.
- Examples of C 1-3 alkoxy groups include, but are not limited to, methoxy, ethoxy, propoxy (including n-propoxy and isopropoxy), and the like.
- C 1-3 alkylamino refers to those alkyl groups containing 1 to 3 carbon atoms attached to the remainder of the molecule through an amino group.
- the C 1-3 alkylamino groups include C 1-2 , C 3 and C 2 alkylamino groups and the like.
- Examples of C 1-3 alkylamino include, but are not limited to, -NHCH 3 , -N(CH 3 ) 2 , -NHCH 2 CH 3 , -N(CH 3 )CH 2 CH 3 , -NHCH 2 CH 2 CH 3 , - NHCH 2 (CH 3 ) 2 and the like.
- C 2-4 alkenyl is used to denote a straight or branched chain hydrocarbon group consisting of 2 to 4 carbon atoms containing at least one carbon-carbon double bond, a carbon-carbon double bond can be located anywhere in the group.
- the C 2-4 alkenyl group includes C 2-3 , C 4 , C 3 and C 2 alkenyl groups, etc.; the C 2-4 alkenyl group may be monovalent, divalent or multivalent.
- Examples of C 2-4 alkenyl groups include, but are not limited to, vinyl, propenyl, butenyl, butadienyl, and the like.
- C 2-3 alkenyl is used to denote a straight or branched chain hydrocarbon group consisting of 2 to 3 carbon atoms containing at least one carbon-carbon double bond, a carbon-carbon double bond can be located anywhere in the group.
- the C 2-3 alkenyl group includes C 3 and C 2 alkenyl groups; the C 2-3 alkenyl group may be monovalent, divalent or multivalent. Examples of C 2-3 alkenyl groups include, but are not limited to, vinyl, propenyl, and the like.
- C 2-4 alkynyl is used to denote a straight or branched chain hydrocarbon group consisting of 2 to 4 carbon atoms containing at least one carbon-carbon triple bond, a carbon-carbon triple bond can be located anywhere in the group.
- the C 2-4 alkynyl groups include C 2-3 , C 4 , C 3 and C 2 alkynyl groups and the like. It can be monovalent, bivalent or multivalent. Examples of C2-4alkynyl groups include, but are not limited to, ethynyl, propynyl, butynyl, and the like.
- C 2-3 alkynyl is used to denote a straight or branched chain hydrocarbon group consisting of 2 to 3 carbon atoms containing at least one carbon-carbon triple bond, a carbon-carbon triple bond can be located anywhere in the group. It can be monovalent, bivalent or multivalent.
- the C 2-3 alkynyl groups include C 3 and C 2 alkynyl groups. Examples of C2-3alkynyl groups include, but are not limited to, ethynyl, propynyl, and the like.
- C 6-10 aryl ring and “C 6-10 aryl group” can be used interchangeably in the present invention
- C 6-10 aryl ring” or C 6-10 aryl group means by A cyclic hydrocarbon group composed of 6 to 10 carbon atoms with a conjugated ⁇ -electron system, which may be a monocyclic, fused bicyclic or fused tricyclic system, wherein each ring is aromatic. It may be monovalent, divalent or polyvalent, and C6-10 aryl groups include C6-9 , C9 , C10 and C6 aryl groups and the like. Examples of C6-10 aryl groups include, but are not limited to, phenyl, naphthyl (including 1-naphthyl and 2-naphthyl, and the like).
- 5-10-membered heteroaryl ring and “5-10-membered heteroaryl” can be used interchangeably in the present invention, and the term “5-10-membered heteroaryl” refers to a ring consisting of 5 to 10 rings.
- a cyclic group composed of atoms with a conjugated ⁇ -electron system, wherein 1, 2, 3 or 4 ring atoms are heteroatoms independently selected from O, S and N, and the rest are carbon atoms. It can be a monocyclic, fused bicyclic or fused tricyclic ring system, wherein each ring is aromatic.
- the nitrogen and sulfur heteroatoms may be optionally oxidized (ie, NO and S(O) p , p is 1 or 2).
- a 5-10 membered heteroaryl group can be attached to the rest of the molecule through a heteroatom or a carbon atom.
- the 5-10-membered heteroaryl groups include 5-8-membered, 5-7-membered, 5-6-membered, 5- and 6-membered heteroaryl groups, and the like.
- Examples of the 5-10 membered heteroaryl group include, but are not limited to, pyrrolyl (including N-pyrrolyl, 2-pyrrolyl and 3-pyrrolyl, etc.), pyrazolyl (including 2-pyrazolyl and 3-pyrrolyl, etc.) azolyl, etc.), imidazolyl (including N-imidazolyl, 2-imidazolyl, 4-imidazolyl and 5-imidazolyl, etc.), oxazolyl (including 2-oxazolyl, 4-oxazolyl and 5- oxazolyl, etc.), triazolyl (1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl, 1H-1,2,4-triazolyl and 4H-1, 2,4-triazolyl, etc.), tetrazolyl, isoxazolyl (3-isoxazolyl, 4-isoxazolyl and 5-isoxazolyl, etc.), thiazolyl (
- the term "4-8 membered heterocycloalkyl" by itself or in combination with other terms denotes a saturated cyclic group consisting of 4 to 8 ring atoms, respectively, of which 1, 2, 3 or 4 ring atoms are heteroatoms independently selected from O, S, and N, and the remainder are carbon atoms, where the nitrogen atom is optionally quaternized, and the nitrogen and sulfur heteroatoms are optionally oxidized (ie, NO and S(O) p , p is 1 or 2). It includes monocyclic and bicyclic ring systems, wherein bicyclic ring systems include spiro, paracyclic and bridged rings.
- a heteroatom may occupy the position of attachment of the heterocycloalkyl to the remainder of the molecule.
- the 4-8 membered heterocycloalkyl includes 4-6 membered, 5-6 membered, 4 membered, 5 membered and 6 membered heterocycloalkyl and the like.
- 4-8 membered heterocycloalkyl examples include, but are not limited to, azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrothienyl ( Including tetrahydrothiophen-2-yl and tetrahydrothiophen-3-yl, etc.), tetrahydrofuranyl (including tetrahydrofuran-2-yl, etc.), tetrahydropyranyl, piperidinyl (including 1-piperidinyl, 2- piperidinyl and 3-piperidyl, etc.), piperazinyl (including 1-piperazinyl and 2-piperazinyl, etc.), morpholinyl (including 3-morpholinyl and 4-morpholinyl, etc.), Dioxanyl, dithianyl, isoxazolidinyl, isothiazolidinyl,
- the term "5-6 membered heterocycloalkenyl" by itself or in combination with other terms respectively denotes a partially unsaturated cyclic group consisting of 5 to 6 ring atoms containing at least one carbon-carbon double bond , whose 1, 2, 3 or 4 ring atoms are heteroatoms independently selected from O, S and N, and the rest are carbon atoms, wherein the nitrogen atom is optionally quaternized, and the nitrogen and sulfur heteroatoms may optionally be Oxidation (ie NO and S(O) p , p is 1 or 2).
- bicyclic ring systems include spiro, paracyclic and bridged rings, any ring of this system is non-aromatic.
- a heteroatom may occupy the position of attachment of the heterocycloalkenyl to the rest of the molecule.
- the 5-6 membered heterocyclenyl includes 5-membered and 6-membered heterocyclenyl and the like. Examples of 5-6 membered heterocycloalkenyl include but are not limited to
- Cn-n+m or Cn - Cn+m includes any particular instance of n to n+ m carbons, eg C1-12 includes C1 , C2 , C3, C 4 , C 5 , C 6 , C 7 , C 8 , C 9 , C 10 , C 11 , and C 12 , also including any range from n to n+ m , eg C 1-12 includes C 1-3 , C 1-6 , C 1-9 , C 3-6 , C 3-9 , C 3-12 , C 6-9 , C 6-12 , and C 9-12 , etc.; in the same way, n yuan to n +m-membered means that the number of atoms in the ring is from n to n+m, for example, 3-12-membered ring includes 3-membered ring, 4-membered ring, 5-membered ring, 6-membered ring, 7-membered ring, 8-membere
- the compounds of the present invention can be prepared by a variety of synthetic methods well known to those skilled in the art, including the specific embodiments enumerated below, embodiments formed in combination with other chemical synthesis methods, and those well known to those skilled in the art Equivalent to alternatives, preferred embodiments include, but are not limited to, the embodiments of the present invention.
- the structure of the compound of the present invention can be confirmed by conventional methods well known to those skilled in the art. If the present invention relates to the absolute configuration of the compound, the absolute configuration can be confirmed by conventional technical means in the art. For example, single crystal X-ray diffraction method (SXRD), the cultured single crystal is collected by Bruker D8 venture diffractometer, the light source is CuK ⁇ radiation, and the scanning mode is: After scanning and collecting relevant data, the crystal structure was further analyzed by the direct method (Shelxs97), and the absolute configuration could be confirmed.
- SXRD single crystal X-ray diffraction method
- the cultured single crystal is collected by Bruker D8 venture diffractometer
- the light source is CuK ⁇ radiation
- the scanning mode is: After scanning and collecting relevant data, the crystal structure was further analyzed by the direct method (Shelxs97), and the absolute configuration could be confirmed.
- the solvent used in the present invention is commercially available.
- the molecular docking process was performed by using Maestro ( Glide SP [1] and default options in version 2017-2).
- the crystal structure PDB:6UT0 of KRAS_G12C in the PDB database was selected, Cys12 was simulated and mutated to Asp12, and after energy optimization, it was used as the docking template.
- To prepare the protein hydrogen atoms were added using the Protein Preparation Wizard module of Maestro [2] and the OPLS3 force field was used.
- the three-dimensional structure of the molecule was generated using LigPrep and energy minimization was performed [3] , and the small molecule conformation was sampled using the confgen module.
- the side length is The cube docking grid. Place reference compounds during molecular docking. Analyze the interaction type of protein receptor and ligand, analyze the interaction type of protein receptor and ligand, and then select and save a reasonable docking conformation according to the calculated docking scrore and binding mode, as shown in Figure 1 to Figure 11 .
- the compound of the present invention has good binding with KRAS G12D .
- Step 4 Synthesis of compound 001 formate salt
- reaction solution was filtered under nitrogen protection, the filter cake was rinsed with 3mL*2 of acetonitrile, and the crude product was prepared, separated and purified (column: Phenomenex Luna 80*30mm*3 ⁇ m; mobile phase: [water (hydrochloric acid)-acetonitrile]; acetonitrile %: 10%-30%, 8 min) to obtain the hydrochloride salt of compound 011.
- Compound 013-2 (0.2g, 231.95 ⁇ mol, 1eq) was added to anhydrous toluene (6mL), benzophenone imine (84.07mg, 463.90 ⁇ mol, 77.85 ⁇ L, 2eq), cesium carbonate (226.72mg) were added , 695.85 ⁇ mol, 3eq), 4,5-bis(diphenylphosphine)-9,9-dimethylxanthene (26.84mg, 46.39 ⁇ mol, 0.2eq), added tris(dibenzylidene) after nitrogen replacement three times (21.24 mg, 23.20 ⁇ mol, 0.1 eq) of dipalladium (21.24 mg, 23.20 ⁇ mol, 0.1 eq), nitrogen was replaced three times, and then stirred at 100° C.
- Step 4 Compound 013 hydrochloride synthesis
- reaction solution was filtered, the filter cake was rinsed with 5 mL of acetonitrile, and the crude product was prepared, separated and purified (column: Phenomenex Luna 80*30mm*3 ⁇ m; mobile phase: [water (hydrochloric acid)-acetonitrile]; acetonitrile %: 10 %-40%, 8 min) to obtain compound 013 hydrochloride.
- Step 1 Compound 014-1 hydrochloride synthesis
- Compound 014-3 (140mg, 141.68 ⁇ mol, 1eq) was added to anhydrous toluene (2.8mL), benzophenone imine (51.35mg, 283.35 ⁇ mol, 47.55 ⁇ L, 2eq), cesium carbonate (138.48mg, 425.03 ⁇ mol, 3eq), 4,5-bis(diphenylphosphine)-9,9-dimethylxanthene (16.40mg, 28.34 ⁇ mol, 0.2eq), added tris(dibenzylidene) after nitrogen replacement three times acetone) dipalladium (12.97 mg, 14.17 ⁇ mol, 0.1 eq) nitrogen was replaced three times and then stirred at 100° C. for 12 hr.
- Step 5 Compound 014-5 hydrochloride synthesis
- Step 10 Compound 015 hydrochloride synthesis
- SFC separation chromatographic column DAICEL CHIRALPAK IC (250mm*30mm, 10 ⁇ m); mobile phase: [0.1% ammonia water-isopropanol]; isopropanol%: 60%-60%, 16min, concentrated under reduced pressure to remove the solvent to obtain Compound 016A and Compound 016B.
- LCMS: (ESI) m/ z 639.3 [M+H] + .
- LCMS: (ESI) m/z 312.9 [M+H] + .
- 1 H NMR 400 MHz, DMSO-d 6 ) ⁇ ppm 8.50 (s, 1H) 8.58 (s, 1H).
- Dissolve 022-3 (70mg, 83.11 ⁇ mol, 1eq) in tetrahydrofuran (1mL) and N,N-dimethylformamide (1mL), then add cesium carbonate (27.08mg, 83.11 ⁇ mol, 1eq), 001-2A ( 15.88mg, 99.73 ⁇ mol, 1.2eq), triethylenediamine (932.23 ⁇ g, 8.31 ⁇ mol, 9.14e-1 ⁇ L, 0.1eq), react at 25°C for 18 hours, add water after the reaction, extract with 100mL ethyl acetate, and use the organic phase with Dry over anhydrous sodium sulfate, filter, and concentrate the filtrate.
- Dissolve 023-3 (118.24mg, 742.74 ⁇ mol, 1eq) in tetrahydrofuran (2mL) and N,N-dimethylformamide (2mL), add cesium carbonate (242.00mg, 742.74 ⁇ mol, 1eq), triethylenedicarbonate Amine (8.33mg, 74.27 ⁇ mol, 8.17 ⁇ L, 0.1eq), 001-2A (0.6g, 742.74 ⁇ mol, 1eq), react at 25°C for 18 hours, add water after the reaction, extract with 100mL of ethyl acetate, the organic phase is anhydrous It was dried over sodium sulfate, filtered, and the filtrate was concentrated.
- Dissolve 023-4 (60mg, 63.36 ⁇ mol, 1eq) in trifluoroacetic acid (7.22mg, 63.36 ⁇ mol, 4.69 ⁇ L, 1eq), stir at 25°C for 1 hour, spin dry the solvent after the reaction, and prepare and separate: chromatographic column: Phenomenex C18 150*40mm*5 ⁇ m; mobile phase: [water (formic acid)-acetonitrile]; acetonitrile%: 5%-35%, 10min to obtain the formate salt of compound 023.
- 024-4 (1.3g, 2.66mmol, 1eq) was dissolved in N,N-dimethylformamide (10mL) and tetrahydrofuran (10mL), then cesium carbonate (867.60mg, 2.66mmol, 1eq) was added, 001- 2A (635.88mg, 3.99mmol, 1.5eq), triethylenediamine (29.87mg, 266.28 ⁇ mol, 29.28 ⁇ L, 0.1eq), stirred at 25°C for 18 hours, extracted with 50mL of ethyl acetate after the reaction, saturated common salt Wash with water, combine the organic phases, dry over anhydrous sodium sulfate, filter, and concentrate the filtrate.
- reaction solution was cooled to room temperature, and 20 mL of the reaction solution was added.
- compound 001-1 400 mg, 1.21 mmol, 1 eq was dissolved in anhydrous N,N-dimethylformamide (10 mL), and N,N-diisopropylethylamine (391.21 mg, 3.03mmol, 527.24 ⁇ L, 2.5eq) and 027-1A (257.03mg, 1.21mmol, 1eq), stirred for 0.5 hours, after the reaction was completed, diluted with ethyl acetate (150mL), washed with saturated brine (30mL), anhydrous Dry over sodium sulfate, separate and dry the organic phase, and remove the organic solvent under reduced pressure to obtain crude product 027-1.
- N,N-dimethylformamide 10 mL
- N,N-diisopropylethylamine 391.21 mg, 3.03mmol, 527.24 ⁇ L, 2.5eq
- 027-1A 257.03mg, 1.21mmol, 1eq
- compound 029-1 50mg, 78.01 ⁇ mol, 1eq
- 001-3A 25.29mg, 93.61 ⁇ mol, 1.2eq
- cesium carbonate 76.25mg, 234.02 ⁇ mol, 3eq
- 1,4-di Pd(PPh 3 ) 4 9.01 mg, 7.80 ⁇ mol, 0.1 eq
- oxane 5 mL
- water 1 mL
- Step 1 Synthesis of Compound 030-1
- Ammonium thiocyanate (2.38g, 31.25mmol, 2.38mL, 1.3eq) was added to acetone (50mL), benzoyl chloride (3.38g, 24.04mmol, 2.79mL, 1eq) was added, the reaction was carried out at 70°C for 0.5 hours, and the temperature was lowered.
- Compound 031-3 (1.0g, 3.77mmol, 1eq) was added to anhydrous tetrahydrofuran (15mL), N,N-diethylisopropylamine (1.22g, 9.43mmol, 1.64mL, 2.5eq) and 4- Dimethylaminopyridine (46.09mg, 377.25 ⁇ mol, 0.1eq), di-tert-butyl dicarbonate (988.01mg, 4.53mmol, 1.04mL, 1.2eq) was added under nitrogen protection, and the reaction was carried out at 20°C for 19 hours.
- reaction solution was then added to 5 mL of water, extracted twice with 3 mL of ethyl acetate, and the crude product was separated and purified by preparative high performance liquid chromatography (chromatographic column: Phenomenex luna C18 80*40mm*3 ⁇ m; mobile phase A: water (hydrochloric acid), Mobile phase B: acetonitrile; run gradient: acetonitrile %: 10%-35%, run time: 7 min) to give compound 031 as the hydrochloride salt.
- p-Methoxybenzylamine (617.64mg, 4.50mmol, 582.68 ⁇ L, 1.2eq) and compound 032-3 (1g, 3.75mmol, 1eq) were added to N,N-dimethylformamide (5mL), followed by Potassium carbonate (1.04g, 7.50mmol, 2eq) was reacted at 80°C for 16 hours. After the reaction, 30mL of water was added to the reaction solution, extracted twice with 20mL of methyl tert-butyl ether, the organic phases were combined, and 30mL of saturated brine was used.
- reaction solution was added to 10mL of formazan tert-butyl ether, washed twice with 10 mL of saturated ammonium chloride, washed with 10 mL of saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain compound 034-2.
- the high performance liquid phase preparation method chromatographic column: Phenomenex Luna 80*30mm*3 ⁇ m; mobile phase: [water (0.04% hydrochloric acid)-acetonitrile]; acetonitrile%: 5%-25% After 8 min, the obtained fraction was added dropwise with ammonia water to adjust pH to 9, concentrated under reduced pressure to remove acetonitrile, extracted with ethyl acetate (50 mL*2), and concentrated under reduced pressure to obtain compound 035.
- control compound stock solution 1 mM
- concentration of the test compound stock solution 10 mM.
- the compound of the present invention has a significant inhibitory effect on KRAS G12D enzyme.
- AGS cells were seeded in a transparent 96-well cell culture plate, 80 ⁇ L of cell suspension per well, each well containing 10,000 cells, the cell plate was placed in a carbon dioxide incubator, and incubated at 37 degrees overnight;
- the compound of the present invention has a significant inhibitory effect on p-ERK in AGS cells.
- GP2D cells were seeded in a transparent 96-well cell culture plate, 80 ⁇ L of cell suspension per well, each well containing 8000 cells, the cell plate was placed in a carbon dioxide incubator, and incubated at 37 degrees overnight;
- the compound of the present invention has a significant inhibitory effect on p-ERK in GP2D cells.
- the purpose of this experiment is to verify the proliferation inhibitory effect of the compounds of the present invention on KRAS G12D mutant GP2D human pancreatic cancer cells.
- Cell line GP2D, DMEM medium, penicillin/streptomycin antibiotics were purchased from Vicente, and fetal bovine serum was purchased from Biosera.
- CellTiter- 3D Cell Viability Assay (3D Cell Viability Chemiluminescence Detection Reagent) reagent was purchased from Promega.
- GP2D cells were seeded in a 96-well U-bottom cell culture plate, 80 ⁇ L of cell suspension per well, which contained 2000 GP2D cells. Cell plates were incubated overnight in a carbon dioxide incubator. The compounds to be tested were diluted 5-fold to the 8th concentration, that is, from 200 ⁇ M to 2.56 nM, and a double-well experiment was set up. Add 78 ⁇ L of medium to the middle plate, and then transfer 2 ⁇ L of each well of the compound to the middle plate according to the corresponding position. After mixing, transfer 20 ⁇ L of each well to the cell plate. Compound concentrations transferred to the cell plate ranged from 1 ⁇ M to 0.0128 nM. The cell plates were placed in a carbon dioxide incubator for 5 days.
- the IC50 value can be obtained by curve fitting with four parameters ("log(inhibitor) vs.response in GraphPad Prism" --Variable slope” mode).
- the compound of the present invention has a significant inhibitory effect on the proliferation of GP2D cells.
- the compounds of the present invention can significantly inhibit the activity of KRAS G12D .
- test compound working solution 400 ⁇ M
- warfarin working solution 400 ⁇ M
- the final concentration of test compound and warfarin in plasma samples is 2 ⁇ M.
- the final concentration of DMSO in the organic phase was 0.5%; 50 ⁇ L of test compound and warfarin plasma samples were pipetted into the sample receiving plate (three parallels), and corresponding volumes of corresponding blank plasma or buffer were added immediately so that each sample well was The final volume of 100 ⁇ L, plasma:dialysis buffer volume ratio was 1:1, then 500 ⁇ L of stop solution was added to these samples, this sample will be used as T0 sample for recovery and stability determination.
- the compound of the present invention has strong binding to plasma protein.
- the compounds of the present invention have good PK properties in mice.
- the compounds of the present invention have good PK properties in rats.
- Compound 014 was mixed with vehicle 20% DMSO/60% PEG400/20% (10% HP- ⁇ -CD in water), vortexed and sonicated to prepare a 4 mg/mL clear solution.
- Candidate compound solutions are administered intravenously.
- Whole blood was collected for a certain period of time, and plasma was prepared.
- the drug concentration was analyzed by LC-MS/MS method, and the pharmacokinetic parameters were calculated. The results are shown in Table 17.
- Compound 014 was mixed with vehicle 15 mg/mL in 20% DMSO/60% PEG400/20% (10% HP- ⁇ -CD in water), vortexed and sonicated to prepare solutions of 6 mg/mL to 15 mg/mL.
- Candidate compound solutions are administered orally.
- Whole blood was collected for a certain period of time, and plasma was prepared.
- the drug concentration was analyzed by LC-MS/MS method, and the pharmacokinetic parameters were calculated. The results are shown in Table 18.
- mice A Balb/c nude mouse model of human colon cancer GP2D cells was established by subcutaneous xenograft tumor, and 0.2 mL (2 ⁇ 10 6 cells) of GP2D cells (plus Matrigel, with a volume ratio of 1:1) were subcutaneously inoculated into each mouse. On the right back of the mice, when the average tumor volume reached 149 mm 3 , group administration was started, with 6 mice in each group. On the day of the experiment, the animals were given the corresponding drugs according to the groups. The first group G1 was set as a negative control group, which was given 5% DMSO+95% (10% HP- ⁇ -CD) by gavage alone, and the second group G2 to the fifth group G5 were given compound 014. The dosage and schedule are shown in the table. 19 shown.
- PO oral
- QD means once a day
- BID means once a day.
- the body weight and tumor size of the animals were measured twice a week, while the clinical symptoms of the animals were observed and recorded every day, and the last weighed animal body weight was referenced for each administration.
- Compound 014 has a significant inhibitory effect on human colon cancer GP2D mouse xenograft tumors.
- the tumor volume inhibition rate TGI (%) of the second group G2 (25 mg/kg, PO, BID) on the 14th day was as follows: 84.2%; the third group G3 (50mg/kg, PO, BID) and the fourth group G4 (150mg/kg, PO, BID) on the 14th day, the tumor volume inhibition rate TGI (%) were 89.4% and 97.3%, respectively ;
- the tumor volume inhibition rate TGI (%) were 91.4%, the detailed results are shown in Table 20.
- N/A means not detected.
Abstract
Description
细胞系 | 肿瘤类型 | 生长特点 | 培养方法 |
AsPC-1 | 胰腺癌 | 贴壁生长 | RPMI 1640+10%FBS |
GP2D | 结肠癌 | 贴壁生长 | DMEM+10%FBS+2mM L-glutamine |
细胞系 | 密度(每孔) |
AsPC-1 | 7000个细胞 |
GP2D | 8000个细胞 |
化合物编号 | KRAS G12D IC 50(nM) |
化合物001的甲酸盐 | 9.2 |
化合物004 | 0.5 |
化合物005的盐酸盐 | 0.1 |
化合物007的盐酸盐 | 0.4 |
化合物008的盐酸盐 | 1.3 |
化合物020的甲酸盐 | 6.6 |
化合物027的盐酸盐 | 38.6 |
化合物编号 | AGS p-ERK IC 50(nM) |
化合物001的甲酸盐 | 291.8 |
化合物004 | 31.4 |
化合物005的盐酸盐 | 147.3 |
化合物006的盐酸盐 | 67.1 |
化合物编号 | GP2D p-ERK IC 50(nM) |
化合物010的盐酸盐 | 0.055 |
化合物011的盐酸盐 | 0.016 |
化合物012的甲酸盐 | 0.71 |
化合物013的盐酸盐 | 0.88 |
化合物014 | 0.43 |
化合物016B | 0.67 |
化合物018的三氟乙酸盐 | 1.6 |
化合物019的盐酸盐 | 21.4 |
化合物022的甲酸盐 | 11.6 |
化合物024的甲酸盐 | 4.4 |
化合物编号 | GP2D IC 50(nM) |
化合物006的盐酸盐 | 2.04 |
化合物010的盐酸盐 | 3.6 |
化合物011的盐酸盐 | 6.2 |
化合物012的甲酸盐 | 0.94 |
化合物024的甲酸盐 | 16 |
化合物编号 | IC 50(nM) |
化合物014 | 11.97 |
化合物016B | 6.23 |
化合物034 | 22.49 |
化合物编号 | Unbound PPB H/D/C/R/M |
010 | 2.9%/2.2%/1.9%/1.3%/2.0% |
014 | 18.5%/3.0%/2.8%/2.0%/4.5% |
供试品 | 010 | 014 |
给药剂量(mg/kg) | 1.03 | 1.28 |
C 0(nM) | 712 | 953 |
T 1/2(h) | 8.1 | 5.7 |
Vd(L/kg) | 25.0 | 25.6 |
Cl(mL/Kg/min) | 61.4 | 77.0 |
AUC 0-inf(nM.h) | 457 | 565 |
供试品 | 010盐酸盐 | 014 |
给药剂量(mg/kg) | 5.54 | 16.0 |
C max(nM) | 54 | 524 |
T max | 1.5 | 2.5 |
T 1/2(h) | 1.6 | 6.0 |
AUC 0-inf(nM.h) | 125 | 1491 |
AUC u(nM.h) | 2.5 | 67.1 |
F% | 5.1 | 20.5 |
供试品 | 014 |
给药剂量(mg/kg) | 1.56 |
C 0(nM) | 971 |
T 1/2(h) | 0.56 |
Vd(L/kg) | 5.89 |
Cl(mL/Kg/min) | 271 |
AUC 0-inf(nM.h) | 150 |
供试品 | 014 |
给药剂量(mg/kg) | 31.7 |
C max(nM) | 182 |
T max | 2.0 |
T 1/2(h) | 6.8 |
AUC 0-inf(nM.h) | 427 |
F% | 12.5 |
供试品 | 014 |
给药剂量(mg/kg) | 1.56 |
C 0(nM) | 971 |
T 1/2(h) | 0.56 |
Vd(L/kg) | 5.89 |
Cl(mL/Kg/min) | 271 |
AUC 0-inf(nM.h) | 150 |
供试品 | 014 |
给药剂量(mg/kg) | 32.1 |
C max(nM) | 439 |
T max | 1.0 |
T 1/2(h) | 10.8 |
AUC 0-inf(nM.h) | 969 |
F% | 16.9 |
Claims (20)
- 式(II)所示化合物或其药学上可接受的盐其中,E 1选自S或-CR 3=CH-;L 1选自-CH 2-和键;T 1选自CH 2、NH和O;T 2选自CH和N;T 3和T 4分别独立地选自CH 2和NH;m、n、p和x分别独立地选自0、1或2;r、v和w分别独立地选自1或2;q、s和u分别独立地选自1、2或3;R 1选自C 6-10芳基和5-10元杂芳基,所述C 6-10芳基和5-10元杂芳基任选被1、2、3、4或5个R b取代;R 2选自H、F、Cl、CN、NH 2、C 1-3烷基和C 1-3烷氧基,所述C 1-3烷基和C 1-3烷氧基任选被1、2或3个卤素取代;R 3选自H、F、Cl、C 1-3烷基、C 1-3烷氧基、C 2-4烯基和环丙基,所述C 1-3烷基、C 1-3烷氧基、C 2-4烯基和环丙基任选被1、2或3个卤素取代;各R a分别独立地选自F、Cl、Br、I和CH 3;各R b分别独立地选自F、Cl、Br、I、OH、NH 2、CN、C 1-3烷基、C 1-3烷氧基、C 2-4烯基和C 2-4炔基,所述C 1-3烷基、C 1-3烷氧基、C 2-4烯基和C 2-4炔基任选被1、2或3个卤素取代;各R e分别独立地选自H、F、Cl、Br、OH、CN、C 1-3烷基、C 1-3烷氧基和-C 1-3烷基-O-C(=O)-C 1-3烷氨基。
- 根据权利要求1所述化合物或其药学上可接受的盐,其中各R b分别独立地选自F、Cl、Br、I、OH、NH 2、CN、CH 3、CH 2CH 3、OCH 3、OCH 2CH 3、-CH=CH 2、-CH 2-CH=CH 2和-C≡CH,所述CH 3、CH 2CH 3、OCH 3、OCH 2CH 3、-CH=CH 2、-CH 2-CH=CH 2和-C≡CH任选被1、2或3个卤素取代。
- 根据权利要求4所述化合物或其药学上可接受的盐,其中各R b分别独立地选自F、Cl、OH、NH 2、CN、CH 3、CF 3、CH 2CH 3和-C≡CH。
- 根据权利要求1所述化合物或其药学上可接受的盐,其中,R 1选自苯基、吡啶基、萘基、喹啉基、苯并噻唑基和苯并噻吩基,所述苯基、吡啶基、萘基、喹啉基、苯并噻唑基和苯并噻吩基任选被1、2、3、4或5个R b取代。
- 根据权利要求1所述化合物或其药学上可接受的盐,其中,R 2选自H、F、Cl、CH 3和OCH 3,所述CH 3和OCH 3任选被1、2或3个卤素取代。
- 根据权利要求1或9所述化合物或其药学上可接受的盐,其中,R 2选自H、F、Cl、OCH 3和OCHF 2。
- 根据权利要求1所述化合物或其药学上可接受的盐,其中,R 3选自H、F、Cl、CH 3、OCH 3、-CH=CH 2和环丙基,所述CH 3、OCH 3、-CH=CH 2和环丙基任选被1、2或3个卤素取代。
- 根据权利要求1或11所述化合物或其药学上可接受的盐,其中,R 3选自H、F、Cl、OCHF 2、-CH=CH 2和环丙基。
- 根据权利要求1所述化合物或其药学上可接受的盐,其中,R 4选自四氢吡咯基和六氢-1H-吡咯里嗪基,所述四氢吡咯基和六氢-1H-吡咯里嗪基被1、2或3个R e取代。
- 根据权利要求1~18任意一项所述的化合物或其药学上可接受的盐,其在制备治疗KRAS G12D突变相关肿瘤药物中的应用。
- 根据权利要求19所述的应用,肿瘤指结直肠癌和胰腺癌。
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2023547791A JP2024505594A (ja) | 2021-02-09 | 2022-02-09 | ピリミジン芳香環化合物 |
CN202280013706.4A CN116888128A (zh) | 2021-02-09 | 2022-02-09 | 嘧啶并芳香环类化合物 |
BR112023015976A BR112023015976A2 (pt) | 2021-02-09 | 2022-02-09 | Compostos de anel aromático de pirimidina |
IL305033A IL305033A (en) | 2021-02-09 | 2022-02-09 | Cyclic aromatic pyrimidine compounds |
CA3207800A CA3207800A1 (en) | 2021-02-09 | 2022-02-09 | Pyrimidine aromatic ring compounds |
KR1020237028837A KR20230136636A (ko) | 2021-02-09 | 2022-02-09 | 피리미딘 방향족 환 화합물 |
EP22752307.3A EP4293027A1 (en) | 2021-02-09 | 2022-02-09 | Pyrimidine aromatic ring compounds |
AU2022219124A AU2022219124A1 (en) | 2021-02-09 | 2022-02-09 | Pyrimidine aromatic ring compounds |
PCT/CN2023/073182 WO2023138662A1 (zh) | 2022-01-21 | 2023-01-19 | 苯并嘧啶类化合物及其应用 |
Applications Claiming Priority (20)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110182357.6 | 2021-02-09 | ||
CN202110182357 | 2021-02-09 | ||
CN202110251656 | 2021-03-08 | ||
CN202110251656.0 | 2021-03-08 | ||
CN202110379326 | 2021-04-08 | ||
CN202110379326.X | 2021-04-08 | ||
CN202110485837 | 2021-04-30 | ||
CN202110485837.X | 2021-04-30 | ||
CN202110825879.3 | 2021-07-21 | ||
CN202110825879 | 2021-07-21 | ||
CN202110975205 | 2021-08-24 | ||
CN202110975205.1 | 2021-08-24 | ||
CN202111136266.5 | 2021-09-27 | ||
CN202111136266 | 2021-09-27 | ||
CN202111283561 | 2021-11-01 | ||
CN202111283561.3 | 2021-11-01 | ||
CN202210072243 | 2022-01-21 | ||
CN202210072243.0 | 2022-01-21 | ||
CN202210113080.6 | 2022-01-29 | ||
CN202210113080 | 2022-01-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022171147A1 true WO2022171147A1 (zh) | 2022-08-18 |
Family
ID=82837454
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2022/075732 WO2022171147A1 (zh) | 2021-02-09 | 2022-02-09 | 嘧啶并芳香环类化合物 |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP4293027A1 (zh) |
JP (1) | JP2024505594A (zh) |
KR (1) | KR20230136636A (zh) |
CN (1) | CN116888128A (zh) |
AU (1) | AU2022219124A1 (zh) |
BR (1) | BR112023015976A2 (zh) |
CA (1) | CA3207800A1 (zh) |
IL (1) | IL305033A (zh) |
WO (1) | WO2022171147A1 (zh) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115141215A (zh) * | 2021-03-30 | 2022-10-04 | 上海德琪医药科技有限公司 | Kras g12d蛋白抑制剂和其用途 |
WO2023039240A1 (en) * | 2021-09-13 | 2023-03-16 | Biomea Fusion, Inc. | IRREVERSIBLE INHIBITORS OF KRas |
WO2023061294A1 (zh) * | 2021-10-13 | 2023-04-20 | 再鼎医药(上海)有限公司 | 含氮杂环类衍生物调节剂、其制备方法及应用 |
WO2023072188A1 (zh) * | 2021-10-29 | 2023-05-04 | 贝达药业股份有限公司 | Kras g12d抑制剂及其在医药上的应用 |
WO2023138662A1 (zh) * | 2022-01-21 | 2023-07-27 | 南京明德新药研发有限公司 | 苯并嘧啶类化合物及其应用 |
WO2023138583A1 (zh) * | 2022-01-21 | 2023-07-27 | 上海湃隆生物科技有限公司 | 杂环类化合物、药物组合物及其应用 |
WO2023152255A1 (en) * | 2022-02-10 | 2023-08-17 | Bayer Aktiengesellschaft | Fused pyrimidines as kras inhibitors |
WO2024008179A1 (en) * | 2022-07-07 | 2024-01-11 | Beigene, Ltd. | Heterocyclic compounds, compositions thereof, and methods of treatment therewith |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110267957A (zh) * | 2017-02-02 | 2019-09-20 | 安斯泰来制药株式会社 | 喹唑啉化合物 |
WO2020113071A1 (en) * | 2018-11-29 | 2020-06-04 | Araxes Pharma Llc | Compounds and methods of use thereof for treatment of cancer |
WO2020177629A1 (zh) * | 2019-03-01 | 2020-09-10 | 劲方医药科技(上海)有限公司 | 螺环取代的嘧啶并环类化合物,其制法与医药上的用途 |
CN112110918A (zh) * | 2019-06-21 | 2020-12-22 | 劲方医药科技(上海)有限公司 | 螺环取代的嘧啶并环类化合物,其制法与医药上的用途 |
WO2021106231A1 (en) * | 2019-11-29 | 2021-06-03 | Taiho Pharmaceutical Co., Ltd. | A compound having inhibitory activity against kras g12d mutation |
WO2022002102A1 (en) * | 2020-06-30 | 2022-01-06 | InventisBio Co., Ltd. | Quinazoline compounds, preparation methods and uses thereof |
CN114031562A (zh) * | 2021-10-31 | 2022-02-11 | 南京碳硅人工智能生物医药技术研究院有限公司 | 一种具有抗肿瘤的吡啶衍生物的工艺优化 |
WO2022047260A1 (en) * | 2020-08-28 | 2022-03-03 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
WO2022061251A1 (en) * | 2020-09-18 | 2022-03-24 | Plexxikon Inc. | Compounds and methods for kras modulation and indications therefor |
-
2022
- 2022-02-09 KR KR1020237028837A patent/KR20230136636A/ko active Search and Examination
- 2022-02-09 IL IL305033A patent/IL305033A/en unknown
- 2022-02-09 JP JP2023547791A patent/JP2024505594A/ja active Pending
- 2022-02-09 CA CA3207800A patent/CA3207800A1/en active Pending
- 2022-02-09 BR BR112023015976A patent/BR112023015976A2/pt unknown
- 2022-02-09 CN CN202280013706.4A patent/CN116888128A/zh active Pending
- 2022-02-09 EP EP22752307.3A patent/EP4293027A1/en active Pending
- 2022-02-09 WO PCT/CN2022/075732 patent/WO2022171147A1/zh active Application Filing
- 2022-02-09 AU AU2022219124A patent/AU2022219124A1/en active Pending
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110267957A (zh) * | 2017-02-02 | 2019-09-20 | 安斯泰来制药株式会社 | 喹唑啉化合物 |
WO2020113071A1 (en) * | 2018-11-29 | 2020-06-04 | Araxes Pharma Llc | Compounds and methods of use thereof for treatment of cancer |
WO2020177629A1 (zh) * | 2019-03-01 | 2020-09-10 | 劲方医药科技(上海)有限公司 | 螺环取代的嘧啶并环类化合物,其制法与医药上的用途 |
CN112110918A (zh) * | 2019-06-21 | 2020-12-22 | 劲方医药科技(上海)有限公司 | 螺环取代的嘧啶并环类化合物,其制法与医药上的用途 |
WO2021106231A1 (en) * | 2019-11-29 | 2021-06-03 | Taiho Pharmaceutical Co., Ltd. | A compound having inhibitory activity against kras g12d mutation |
WO2022002102A1 (en) * | 2020-06-30 | 2022-01-06 | InventisBio Co., Ltd. | Quinazoline compounds, preparation methods and uses thereof |
WO2022047260A1 (en) * | 2020-08-28 | 2022-03-03 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
WO2022061251A1 (en) * | 2020-09-18 | 2022-03-24 | Plexxikon Inc. | Compounds and methods for kras modulation and indications therefor |
CN114031562A (zh) * | 2021-10-31 | 2022-02-11 | 南京碳硅人工智能生物医药技术研究院有限公司 | 一种具有抗肿瘤的吡啶衍生物的工艺优化 |
Non-Patent Citations (2)
Title |
---|
DATABASE Registry CAS; ANONYMOUS : " Phenol, 3-[4-(2,7-diazaspiro[3.5]non-7-yl)-6-methoxy-2-[[(2S)-1-methyl-2- pyrrolidinyl]methoxy]-7-quinazolinyl]-4-fluoro- ", XP055958220, retrieved from STN * |
DATABASE REGISTRY CAS; ANONYMOUS : "INDEX NAME NOT YET ASSIGNED ", XP055958216, retrieved from STN * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115141215A (zh) * | 2021-03-30 | 2022-10-04 | 上海德琪医药科技有限公司 | Kras g12d蛋白抑制剂和其用途 |
CN115141215B (zh) * | 2021-03-30 | 2023-09-15 | 上海德琪医药科技有限公司 | Kras g12d蛋白抑制剂和其用途 |
WO2023039240A1 (en) * | 2021-09-13 | 2023-03-16 | Biomea Fusion, Inc. | IRREVERSIBLE INHIBITORS OF KRas |
WO2023061294A1 (zh) * | 2021-10-13 | 2023-04-20 | 再鼎医药(上海)有限公司 | 含氮杂环类衍生物调节剂、其制备方法及应用 |
WO2023072188A1 (zh) * | 2021-10-29 | 2023-05-04 | 贝达药业股份有限公司 | Kras g12d抑制剂及其在医药上的应用 |
WO2023138662A1 (zh) * | 2022-01-21 | 2023-07-27 | 南京明德新药研发有限公司 | 苯并嘧啶类化合物及其应用 |
WO2023138583A1 (zh) * | 2022-01-21 | 2023-07-27 | 上海湃隆生物科技有限公司 | 杂环类化合物、药物组合物及其应用 |
WO2023152255A1 (en) * | 2022-02-10 | 2023-08-17 | Bayer Aktiengesellschaft | Fused pyrimidines as kras inhibitors |
WO2024008179A1 (en) * | 2022-07-07 | 2024-01-11 | Beigene, Ltd. | Heterocyclic compounds, compositions thereof, and methods of treatment therewith |
Also Published As
Publication number | Publication date |
---|---|
IL305033A (en) | 2023-10-01 |
BR112023015976A2 (pt) | 2023-12-12 |
AU2022219124A1 (en) | 2023-08-31 |
EP4293027A1 (en) | 2023-12-20 |
KR20230136636A (ko) | 2023-09-26 |
JP2024505594A (ja) | 2024-02-06 |
CN116888128A (zh) | 2023-10-13 |
CA3207800A1 (en) | 2022-08-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2022171147A1 (zh) | 嘧啶并芳香环类化合物 | |
WO2021180181A1 (zh) | 嘧啶并杂环类化合物及其应用 | |
WO2022170999A1 (zh) | 吡啶[4,3-d]嘧啶类化合物 | |
CN113801114B (zh) | 稠合二环杂芳基类衍生物、其制备方法及其在医药上的应用 | |
WO2020200316A1 (zh) | 作为ret抑制剂的吡唑并吡啶类化合物及其应用 | |
WO2021259331A1 (zh) | 八元含n杂环类化合物 | |
JP2023517393A (ja) | タンパク質分解調整剤およびその使用方法 | |
WO2022161443A1 (zh) | 嘧啶并吡喃类化合物 | |
WO2019157879A1 (zh) | 作为trk抑制剂的杂环化合物 | |
CN111018861A (zh) | 吡咯并嘧啶化合物 | |
WO2023138662A1 (zh) | 苯并嘧啶类化合物及其应用 | |
CN117642407A (zh) | 一种含氮杂环化合物、其制备方法、中间体及应用 | |
WO2021244634A1 (zh) | 咪唑并吡啶类化合物及其用途 | |
WO2022063308A1 (zh) | 一类1,7-萘啶类化合物及其应用 | |
WO2023020605A1 (zh) | 喜树碱衍生物、其药物组合物及其应用 | |
WO2022171143A1 (zh) | 5,6,7,8-四氢吡啶[3,4-d]嘧啶化合物 | |
WO2021104441A1 (zh) | 作为egfr激酶抑制剂的多芳基化合物 | |
WO2023217045A1 (zh) | 选择性抑制parp1的氟代喹喔啉酮衍生物 | |
CN112955453B (zh) | 作为选择性Trk抑制剂的吡唑并嘧啶衍生物 | |
WO2023280317A1 (zh) | 苄氨基三并环类化合物及其应用 | |
WO2022262782A1 (zh) | 戊二酰亚胺取代的异噁唑稠环化合物及其应用 | |
WO2023001069A1 (zh) | 大环酰胺类化合物及其应用 | |
WO2021197467A1 (zh) | 多靶点的抗肿瘤化合物及其制备方法和应用 | |
CN115667275A (zh) | 含硼化合物及其应用 | |
WO2024012456A1 (zh) | 哌嗪桥取代的杂环并嘧啶类化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22752307 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280013706.4 Country of ref document: CN Ref document number: 305033 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18276334 Country of ref document: US Ref document number: 2023547791 Country of ref document: JP Ref document number: 3207800 Country of ref document: CA Ref document number: MX/A/2023/009278 Country of ref document: MX |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112023015976 Country of ref document: BR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202392079 Country of ref document: EA |
|
ENP | Entry into the national phase |
Ref document number: 20237028837 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020237028837 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2022219124 Country of ref document: AU Date of ref document: 20220209 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022752307 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022752307 Country of ref document: EP Effective date: 20230911 |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01E Ref document number: 112023015976 Country of ref document: BR Free format text: APRESENTE NOVAS FOLHAS DO RELATORIO DESCRITIVO MODIFICADO ADAPTADAS AO ART. 40 DA INSTRUCAO NORMATIVA/INPI/NO 31/2013, UMA VEZ QUE O CONTEUDO ENVIADO NA PETICAO NO 870230070113 DE 08/08/2023 ENCONTRA-SE FORA DA NORMA NO QUE SE REFERE A NUMERACAO DOS PARAGRAFOS. HA ERRO DE NUMERACAO DE PARAGRAFO APOS O NUMERO PARAGRAFO NO 130. A EXIGENCIA DEVE SER RESPONDIDA EM ATE 60 (SESSENTA) DIAS DE SUA PUBLICACAO E DEVE SER REALIZADA POR MEIO DA PETICAO GRU CODIGO DE SERVICO 207. |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11202306009U Country of ref document: SG |
|
ENP | Entry into the national phase |
Ref document number: 112023015976 Country of ref document: BR Kind code of ref document: A2 Effective date: 20230808 |